PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Over 25 years have passed since peroxisome proliferators‐activated receptors (PPARs), were first described. Like other members of the nuclear receptors superfamily, PPARs have been defined as critical sensors and master regulators of cellular metabolism. Recognized as ligand‐activated transcription factors, they are involved in lipid, glucose and amino acid metabolism, taking part in different cellular processes, including cellular differentiation and apoptosis, inflammatory modulation and attenuation of acute and chronic neurological damage in vivo and in vitro. Interestingly, PPAR activation can simultaneously reprogram the immune response, stimulate metabolic and mitochondrial functions, promote axonal growth, induce progenitor cells to differentiate into myelinating oligodendrocytes, and improve brain clearance of toxic molecules such as β‐amyloid peptide. Although the molecular mechanisms and cross‐talk with different molecular pathways are still the focus of intense research, PPAR s are considered potential therapeutic targets for several neuropathological conditions, including degenerative disorders such as A lzheimer's, P arkinson's and H untington's disease. This review considers recent advances regarding PPARs, as well as new PPAR agonists. We focus on the mechanisms behind the neuroprotective effects exerted by PPARs and summarise the roles of PPARs in different pathologies of the central nervous system, especially those associated with degenerative and inflammatory mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…has been described as the major neurotoxic agent in AD, and the Aβ aggregates are commonly surrounded by dystrophic neurites and reactive glial cells (Lacor et al., 2004; Haass & Selkoe, 2007; Cerpa, Dinamarca & Inestrosa, 2008; Li, Shankar & Selkoe, 2010; Dinamarca, Ríos & Inestrosa, 2012).”
BackgroundEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727 · cited 1×
“More than 150 genes have been reported to be linked to NF-κB, with a high proportion acting as pro-inflammatory genes (Pahl, 1999).”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“PPARs were discovered in 1990, when I. Issemann and S. Green cloned a receptor that was activated by peroxisome proliferators (PPs) from a mouse liver genetic library (Lazarow & De Duve, 1976; Lock, Mitchell & Elcombe, 1989; Issemann & Green, 1990).”
MethodNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“…disorder characterised by progressive memory loss and cognitive impairment associated with selective neuronal death in the brain areas necessary for memory and learning (Morgan et al., 2007; Salmon & Bondi, 2009; Ballard et al., 2011; Serrano-Pozo et al., 2011; Godoy et al., 2014b).”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“PPARα activators, as well as some fibrates, have been reported to be associated with increases in markers of cardiovascular, renal, and hepatic dysfunction and rhabdomyolysis (Davidson et al., 2007; Rubenstrunk et al., 2007; Ginsberg et al., 2010; Oshima, 2011).”
BackgroundAdapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 1×
“The main functions of the ER are to maintain proteostasis (Balch et al., 2008) and regulate intracellular Ca2+ concentration.”
BackgroundBallard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 1×
“Fatty acids and eicosanoids can activate PPARs, inducing the regulation of lipid and fat metabolism in the liver (Gottlicher et al., 1992; Forman, Chen & Evans, 1997; Kliewer et al., 1997; Wahli et al., 1999).”
BackgroundForman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Mitochondrial fusion and fission in cell life and death
Westermann, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3013 · Cited by 2,002 · cited 2×
“Considering that di novo mitochondrial genesis is rare, damaged mitochondria can either be eliminated through mitophagia or can be recovered through mitochondrial biogenesis, a complex process including mitochondrial fusion–fission phenomena (Westermann, 2010; Elgass et al., 2012).”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“Biological Reviews 92 (2017) 2046–2069 © 2017 Cambridge Philosophical Society PPARs are part of the metabolic sub-family of nuclear receptors, which includes steroid, thyroid hormone, vitamin D and retinoid receptors (Willson et al., 2000).”
BackgroundRegulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Südhof, T. C. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.012 · Cited by 1,251 · cited 2×
“Current treatments are palliative and are based on attempts to restore the electrochemical balance of neurons with the appropriate levels of neurotransmitters to ensure their function (Sheng, Sabatini & Südhof, 2012).”
BackgroundNeurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle
Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.022 · Cited by 1,197
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“It is known that NSAIDs can act through this particular nuclear receptor (Lehmann et al., 1997; Heneka et al., 2007).”
BackgroundManczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 1×
“In AD, Aβ-peptide accumulates within mitochondria leading to mitochondrial dysfunction and fragmentation (Manczak et al., 2006; Reddy & Beal, 2008; Paula-Lima et al., 2011).”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 8×
“…been shown to enhance Aβ clearance through increased expression of apolipoprotein E (ApoE) as well as its transporter proteins, ATP-binding cassette submember A1 (ABCA1) and ABCG1, and neuronal low density lipoprotein receptor-related protein 1 (LRP1) (Cramer et al., 2012; Tachibana et al., 2015).”
BackgroundInfluentialNeurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 1×
“Aβ-induced synaptic failure is associated with the loss of synaptic proteins, which further contributes to the progression of the disease (Scheff et al., 2007; Mucke & Selkoe, 2012; Borlikova et al., 2013).”
BackgroundLiver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978 · cited 1×
“…underlying mechanisms, potentially including interactions of PPARγ :RXR and LXR:RXR heterodimers with cell signalling pathways related to neuron and synaptic recovery, such as Wnt signalling, might play a critical role in the effects observed with the RXR agonist (Zelcer & Tontonoz, 2006).”
BackgroundReddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Neuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786 · cited 16×
“Fatty acids and eicosanoids can activate PPARs, inducing the regulation of lipid and fat metabolism in the liver (Gottlicher et al., 1992; Forman, Chen & Evans, 1997; Kliewer et al., 1997; Wahli et al., 1999).”
BackgroundInfluentialGlial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 1×
“…to play an important role in AD aetiology (Tan et al., 2007) and substantial evidence suggests that it is also involved in the pathogenesis of PD (McGeer & McGeer, 2007; Tansey et al., 2008; Glass et al., 2010), Biological Reviews 92 (2017) 2046–2069 © 2017 Cambridge Philosophical…”
BackgroundKim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
Synapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 1×
“Pathological modifications of the presynaptic neurotransmitter-releasing machinery and/or altered expression of specific postsynaptic proteins such as postsynaptic density protein-95 (PSD-95) underlie the synaptic impairment observed in AD (Sheng et al., 2012; Südhof, 2012, 2013).”
BackgroundNeuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433 · cited 1×
“In the brain, PPARγ -agonists reduce Aβ- and cytokine-mediated neuroinflammation and neurotoxicity in vitro and in vivo (Heneka et al., 2007, 2010).”
BackgroundMechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377 · cited 3×
“Activation of the RXR:PPAR complex requires the removal of transcriptional co-repressors and the addition of co-activators such as PGC-1α (Delerive et al., 2002; Mulholland et al., 2005).”
BackgroundLi, M., Pascual, G., & Glass, C. K. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.13.4699-4707.2000 · Cited by 377
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 3×
“…outcomes in several models of neurodegenerative disorders, including improved cognitive performance in animals (Landreth, 2007; Cramer et al., 2012; Mandrekar-Colucci et al., 2012; Inestrosa et al., 2013; Skerrett et al., 2015) and patients (Landreth, 2007; Bernardo & Minghetti, 2008;…”
BackgroundNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · cited 3×
“In microglia and macrophages, PPARγ activation inhibits pro-inflammatory gene expression (Yamanaka et al., 2012).”
BackgroundLee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319 · cited 3×
“INT131 is a promising selective modulator of PPARγ and in humans and in animal models of T2DM can restore blood glucose levels and plasma insulin levels without major increases in body mass or plasma volume, or decreases in bone density (Kim et al., 2009; Lee et al., 2012; Taygerly et al., 2013).”
BackgroundControl of glial immune function by neurons
Neumann, H. (2001) · Glia · doi:10.1002/glia.1108 · Cited by 319
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317 · cited 3×
“However, several authors have observed similar PPAR-mediated effects in both animal models and human cells, as demonstrated by several clinical trials (Heneka & Landreth, 2007).”
BackgroundResultSafety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309 · cited 2×
“PPARα activators, as well as some fibrates, have been reported to be associated with increases in markers of cardiovascular, renal, and hepatic dysfunction and rhabdomyolysis (Davidson et al., 2007; Rubenstrunk et al., 2007; Ginsberg et al., 2010; Oshima, 2011).”
BackgroundPioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286 · cited 1×
“…and meta-analyses of patients with T2DM treated with rosiglitazone indicated an increased risk of coronary heart disease (Lago, Singh & Nesto, 2007; Nissen & Wolski, 2007; Singh, Loke & Furberg, 2007) associated with peripheral oedema (Nikolaidis & Levine, 2004), macular oedema (Kendall &…”
BackgroundNeuronal damage in brain inflammation
Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R., & Zipp, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.185 · Cited by 249 · cited 1×
“…© 2017 Cambridge Philosophical Society both astrocytes and microglia, and although neurons express lower levels of PPARγ , it has been reported that activation of this nuclear receptor also diminished the expression of neuronal iNOS (Heneka, Klockgether & Feinstein, 2000; Aktas et al., 2007).”
BackgroundGene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13656 · Cited by 187
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
Morgan, L., Shah, B., Rivers, L. E., Barden, L., Groom, A. J., Chung, R., Higazi, D., Desmond, H., Smith, T., & Staddon, J. M. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.051 · Cited by 118 · cited 1×
“…disorder characterised by progressive memory loss and cognitive impairment associated with selective neuronal death in the brain areas necessary for memory and learning (Morgan et al., 2007; Salmon & Bondi, 2009; Ballard et al., 2011; Serrano-Pozo et al., 2011; Godoy et al., 2014b).”
BackgroundInterleukins, Inflammation, and Mechanisms of Alzheimer's Disease
Weisman, D., Hakimian, E., & Ho, G. J. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74020-1 · Cited by 95
Nuclear receptors in neurodegenerative diseases
Skerrett, R., Malm, T., & Landreth, G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.019 · Cited by 94 · cited 26×
“The behavioural improvements suggest that additional underlying mechanisms, potentially including interactions of PPARγ :RXR and LXR:RXR heterodimers with cell signalling pathways related to neuron and synaptic recovery, such as Wnt signalling, might play a critical role in the effects observed with the RXR agonist (Z…”
BackgroundInfluentialMalm, T., Mariani, M., Donovan, L. J., Neilson, L., & Landreth, G. E. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0229-9 · Cited by 77
Cited by
Zhao, Y., Zhang, J., Zheng, Y., Zhang, Y., Zhang, X. J., Wang, H., Du, Y., Guan, J., Wang, X., & Fu, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02250-8 · Cited by 348
Wójtowicz, S., Strosznajder, A. K., Jeżyna, M., & Strosznajder, J. B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-02993-5 · Cited by 327
Myelin lipid metabolism and its role in myelination and myelin maintenance
Barnes-Vélez, J. A., Aksoy Yasar, F. B., & Hu, J. (2023) · The Innovation · doi:10.1016/j.xinn.2022.100360 · Cited by 73
Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
Nisbett, K. E., & Pinna, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00998 · Cited by 37
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Metadata
- Authors
- Zolezzi, J. M., Santos, M. J., Bastías‐Candia, S., Pinto, C., Godoy, J. A., & Inestrosa, N. C.
- Venue
- Biological Reviews
- Publisher
- Wiley
- Published
- 2017-02-20
- Volume
- 92
- Issue
- 4
- Pages
- 2046-2069
- ISSN
- 0006-3231 (ISSN-L)
- 1464-7931
- 1469-185X
- OpenAlex
- W2590259245
- Cited by
- 122
- References
- 64
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.